Kurve Technology Announces Agreement with DARA BioSciences

Share Article

Kurve Technology, Inc., a leader in nasal drug delivery devices, today announced the signing of an agreement with development-stage pharmaceutical company DARA BioSciences, Inc. (DBI).

News Image
DARA Biosciences’ research and development is the type of leading-edge pharmaceutical science for which our devices were developed

Kurve Technology, Inc., a leader in nasal drug delivery devices, today announced the signing of an agreement with development-stage pharmaceutical company DARA BioSciences, Inc. (DBI). DBI focuses on the treatment of metabolic diseases, central nervous system disorders and medical devices.

“We are impressed with the quality and flexibility of Kurve’s technology platform and excited about the combining Kurve’s drug delivery technology platform with DARA’s pharmaceutical formulations,” commented John Didsbury, Executive Vice President of DARA BioSciences.

“DARA Biosciences’ research and development is the type of leading-edge pharmaceutical science for which our devices were developed ,” said Marc Giroux, Chairman and Chief Executive Officer of Kurve Technology, Inc. “We are thrilled to be working with the innovative team at DARA.”

Incorporating patented Controlled Particle Dispersion™ and intelligent nasal drug delivery technologies, Kurve Technology’s ViaNase electronic atomizer intranasally delivers topical, systemic and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices such as spray pumps. ViaNase is the first nasal drug delivery device that saturates the entire nasal cavity, allowing delivery to the paranasal sinuses. In addition, ViaNase limits peripheral deposition of pharmaceutical formulations into the lungs or stomach. Kurve Technology’s most recent device offering - ViaNase ID™ - incorporates drug pedigree confirmation, lock-out technology, and an electronic display to curb counterfeit drug use and abuse while improving patient compliance.

About Kurve Technology, Inc.

Kurve Technology, Inc. offers pharmaceutical companies innovative nasal delivery systems for local and systemic medical therapies. Kurve’s Controlled Particle Dispersion (CPD)™ technology intranasally delivers formulations with far greater efficacy and efficiency than traditional methods. The ViaNase product line of intelligent atomizers incorporates CPD to deliver a wide range of compounds, aiding the more than 200 million patients who suffer from such medical conditions as allergic rhinitis, chronic rhinosinusitis, sexual dysfunction, migraine headache, obesity, and CNS disease. Kurve Technology is headquartered in Bothell, WA with an office in Research Triangle Park, NC. For additional information, please visit http://www.kurvetech.com.

About DARA BioSciences

DARA BioSciences, Inc. (DBI), incorporated in Delaware in July 2002, is a development stage company that acquires and develops therapeutic candidates and medical technologies directly or through subsidiaries and is focused on the treatment of metabolic diseases, central nervous system disorders and cardiovascular indications. DBI is the parent company to Signum Pharmaceuticals, OnsetThera, Inc., NYVARA Pharmaceuticals, Inc., MIKKO Pharmaceuticals, and DARA Therapeutics, Inc. Additionally, DBI holds positions in Medeikon Corp., Surgi-Vision, Inc., SpineMedica, Inc. and Medivation, Inc.

Visit the DARA BioSciences, Inc. web site at http://www.DaraBiosciences.com for additional information.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks of testing of drugs for proof of principle, risk that the parties will not be able to negotiate mutually acceptable definitive agreements, risks of regulatory review and clinical trials, competition, market acceptance for approved products, if any, and intellectual property risks.

Contact:

Christine Slocumb

Principal, The onQuest Group

425-949-4012

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christine Slocumb
Visit website